When did Immunoprecise Antibodies report Q3 2025 earnings?

Immunoprecise Antibodies (HYFT) reported Q3 2025 earnings on September 15, 2025 before market open.

What were Immunoprecise Antibodies's Q3 2025 revenue and EPS?

Immunoprecise Antibodies reported revenue of $2.3M and diluted EPS of $-0.07 for Q3 2025.

Revenue missed the consensus estimate of $7.3M by $5.0M. EPS missed the consensus estimate of $-0.04 by $0.03.

Compared to the same quarter a year prior, revenue declined 39.5% from $3.8M a year earlier and diluted EPS grew 36.4% from $-0.11.

Reported September 15, 2025 · Before market open

Revenue estimate$7.3M

EPS estimate-$0.04

Jul 23, 2026 (in a month)

Revenue estimate$3.2M

EPS estimate-$0.05

Q3 2025$2.3MMiss by $5.0M

Q3 2025-$0.07Miss by $0.03

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Immunoprecise Antibodies report Q3 2025 earnings?: Immunoprecise Antibodies (HYFT) reported Q3 2025 earnings on September 15, 2025 before market open.
What were Immunoprecise Antibodies's Q3 2025 revenue and EPS?: Immunoprecise Antibodies reported revenue of $2.3M and diluted EPS of $-0.07 for Q3 2025.
Did Immunoprecise Antibodies beat estimates in Q3 2025?: Revenue missed the consensus estimate of $7.3M by $5.0M. EPS missed the consensus estimate of $-0.04 by $0.03.
How did Immunoprecise Antibodies's Q3 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 39.5% from $3.8M a year earlier and diluted EPS grew 36.4% from $-0.11.